Active Biotech AB Stock Xetra
Equities
BTPC
SE0001137985
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
07-01 | Active Biotech Enters Agreement for A Clinical Study of Tasquinimod in Myelofibrosis | CI |
05-22 | Active Biotech Secures Exclusive Licensing Rights to Multiple Myeloma Drug | MT |
Sales 2024 * | - | Sales 2025 * | 15.6M 1.47M 1.37M 2.02M | Capitalization | 175M 16.51M 15.38M 22.69M |
---|---|---|---|---|---|
Net income 2024 * | -42M -3.96M -3.69M -5.44M | Net income 2025 * | -35M -3.3M -3.07M -4.53M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 0 0 | Net cash position 2025 * | - 0 0 0 | EV / Sales 2025 * | 11.2 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 70.39% |
Managers | Title | Age | Since |
---|---|---|---|
Helén Tuvesson
CEO | Chief Executive Officer | 62 | 97-12-31 |
Hans Kolam
DFI | Director of Finance/CFO | 73 | 99-12-31 |
Erik Vahtola
CTO | Chief Tech/Sci/R&D Officer | - | 21-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Uli Alf Hacksell
BRD | Director/Board Member | 74 | 19-05-22 |
Director/Board Member | 50 | 19-12-31 | |
Michael Shalmi
CHM | Chairman | 59 | 19-05-22 |
1st Jan change | Capi. | |
---|---|---|
+15.82% | 121B | |
+20.35% | 113B | |
+17.47% | 26.02B | |
-25.31% | 19.39B | |
-19.51% | 15.91B | |
-19.67% | 15.09B | |
-46.87% | 15.06B | |
+62.55% | 14.93B | |
+6.34% | 13.85B |
- Stock Market
- Equities
- ACTI Stock
- BTPC Stock